Učitavanje...
Aldose reductase inhibitor, fidarestat prevents doxorubicin-induced endothelial cell death and dysfunction
Despite doxorubicin (Dox) being one of the most widely used chemotherapy agents for breast, blood and lung cancers, its use in colon cancer is limited due to increased drug resistance and severe cardiotoxic side effects that increase mortality associated with its use at high doses. Therefore, better...
Spremljeno u:
| Izdano u: | Biochem Pharmacol |
|---|---|
| Glavni autori: | , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5866779/ https://ncbi.nlm.nih.gov/pubmed/29458045 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bcp.2018.02.018 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|